SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of some unusual options trading on Monday. Traders acquired 48,643 put options on the stock. This represents an increase of approximately 19% compared to the average volume of 40,961 put options.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Nykredit A S acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at about $27,000. GAMMA Investing LLC lifted its stake in shares of SELLAS Life Sciences Group by 293.2% in the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after buying an additional 1,630 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares in the last quarter. Wealthfront Advisers LLC purchased a new position in shares of SELLAS Life Sciences Group in the first quarter worth about $48,000. Finally, Principal Financial Group Inc. acquired a new position in SELLAS Life Sciences Group during the first quarter worth about $53,000. 17.38% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on SLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Analysis on SELLAS Life Sciences Group
Key SELLAS Life Sciences Group News
Here’s some of the latest news about SLS:
- Positive Sentiment: SELLAS plans to discuss the results and potential accelerated filing with the FDA, and is preparing for a Biologics License Application submission in the first half of 2027. The trial win provides Phase 3 validation for GPS, though approval is not assured. SELLAS Phase 3 trial coverage
- Neutral Sentiment: Call-option buying surged to 261,202 contracts, about 522% above typical volume, signaling heightened speculative activity but not necessarily a durable change in fundamentals.
- Negative Sentiment: SELLAS proposed a $150 million underwritten public offering after the rally. Issuing shares could dilute existing shareholders, and reports said the stock fell on the financing announcement. Proposed public offering
SELLAS Life Sciences Group Trading Up 156.4%
Shares of NASDAQ:SLS opened at $19.15 on Wednesday. The business has a 50 day moving average of $11.01 and a two-hundred day moving average of $8.87. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $24.89. The company has a market capitalization of $3.90 billion, a PE ratio of -95.75 and a beta of 2.73.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05).
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Further Reading
- Five stocks we like better than SELLAS Life Sciences Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
